← Back to Search

External Beam Radiation

Preoperative APBI for Breast Cancer

N/A
Waitlist Available
Led By Adam Currey, MD
Research Sponsored by Medical College of Wisconsin
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Pathologically proven diagnosis of invasive breast cancer, clinically stage I-II
Female
Must not have
Estrogen receptor negative disease
American Joint Committee on Cancer (AJCC) clinical T3, N1-3, M1, stage IIB, stage III or stage IV breast cancer
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is studying if it's feasible to give accelerated partial breast irradiation (APBI) before a lumpectomy. APBI is when a smaller volume of breast tissue is exposed to radiation. The trial is using 3D conformal external beam irradiation, which uses an X-ray beam to deliver the radiation dose. MRI will be used to plan the treatment instead of CT imaging.

Who is the study for?
This trial is for women over 40 with early-stage breast cancer (stage I-II), who have not been treated yet. They must be estrogen receptor positive, and can have either her2 positive or negative tumors. Participants should not be pregnant, willing to use contraception during radiation therapy, and without a history of certain other cancers or severe health conditions.
What is being tested?
The study tests if giving accelerated partial breast irradiation (APBI) using MRI before lumpectomy surgery is feasible. This could mean less breast tissue gets exposed to radiation compared to traditional methods where APBI follows the surgery.
What are the potential side effects?
Potential side effects may include skin changes like redness and irritation at the treatment site, fatigue, discomfort in the breast area, and rare risks associated with MRI such as allergic reactions to contrast material used during imaging.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My breast cancer is confirmed and is in the early stages (I or II).
Select...
I am female.
Select...
My cancer is estrogen receptor positive.
Select...
My condition involves only one area or organ.
Select...
I was diagnosed with invasive ductal carcinoma through a biopsy.
Select...
My lymph nodes are normal on exams and ultrasound, with any suspicious ones biopsied.
Select...
I can take care of myself and am up more than 50% of my waking hours.
Select...
I've had a full check-up, breast exams, mammograms, and lymph node checks for breast cancer with no signs of it spreading far.
Select...
I am 40 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My cancer is not driven by estrogen.
Select...
My breast cancer is at an advanced stage (IIB, III, or IV).
Select...
My breast cancer is non-invasive.
Select...
My breast cancer is not the common type but rather a rare form like sarcoma or lymphoma.
Select...
I have breast cancer in more than one location.
Select...
My breast cancer is aggressive (grade 3).
Select...
I've had radiation therapy in the same chest area before.
Select...
I have a known BRCA gene mutation.
Select...
I do not have severe health issues like recent heart problems, serious infections, or liver problems.
Select...
I have a connective tissue disorder like lupus.
Select...
I have Paget's disease of the nipple.
Select...
My breast cancer is invasive lobular carcinoma.
Select...
I need considerable assistance and frequent medical care.
Select...
I am a male diagnosed with breast cancer.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Postoperative Complications Following
Secondary study objectives
Overall Survival
Re-excision of Tumor.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Radiation Therapy followed by LumpectomyExperimental Treatment1 Intervention
Phase II-Preoperative MRI-BasedRadiation followed by Lumpectomy
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Phase II - Preoperative Radiation followed by Lumpectomy.
2009
N/A
~40

Find a Location

Who is running the clinical trial?

Medical College of WisconsinLead Sponsor
635 Previous Clinical Trials
1,181,663 Total Patients Enrolled
14 Trials studying Breast Cancer
409,434 Patients Enrolled for Breast Cancer
Adam Currey, MDPrincipal InvestigatorMedical College of Wisconsin

Media Library

Accelerated Partial Breast Irradiation (External Beam Radiation) Clinical Trial Eligibility Overview. Trial Name: NCT02728076 — N/A
Breast Cancer Research Study Groups: Radiation Therapy followed by Lumpectomy
Breast Cancer Clinical Trial 2023: Accelerated Partial Breast Irradiation Highlights & Side Effects. Trial Name: NCT02728076 — N/A
Accelerated Partial Breast Irradiation (External Beam Radiation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02728076 — N/A
~4 spots leftby Dec 2025